These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 17106785)

  • 41. Risedronate for the prevention of fractures in postmenopausal osteoporosis.
    Sickels JM; Nip CS
    Ann Pharmacother; 2002 Apr; 36(4):664-70. PubMed ID: 11918518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
    Wells G; Cranney A; Peterson J; Boucher M; Shea B; Robinson V; Coyle D; Tugwell P
    Cochrane Database Syst Rev; 2008 Jan; (1):CD004523. PubMed ID: 18254053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
    J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
    Blouin J; Dragomir A; Fredette M; Ste-Marie LG; Fernandes JC; Perreault S
    Osteoporos Int; 2009 Sep; 20(9):1571-81. PubMed ID: 19107385
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
    McClung MR; Geusens P; Miller PD; Zippel H; Bensen WG; Roux C; Adami S; Fogelman I; Diamond T; Eastell R; Meunier PJ; Reginster JY;
    N Engl J Med; 2001 Feb; 344(5):333-40. PubMed ID: 11172164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Lin TC; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differences in persistence among different weekly oral bisphosphonate medications.
    Sheehy O; Kindundu CM; Barbeau M; LeLorier J
    Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preventing osteoporosis-related fractures: an overview.
    Gass M; Dawson-Hughes B
    Am J Med; 2006 Apr; 119(4 Suppl 1):S3-S11. PubMed ID: 16563939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: review of the literature.
    Iwamoto J; Sato Y; Takeda T; Matsumoto H
    Drugs Aging; 2012 Mar; 29(3):191-203. PubMed ID: 22372723
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Risedronate for treatment of osteoporosis].
    Hagino H
    Nihon Rinsho; 2009 May; 67(5):948-53. PubMed ID: 19432115
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Summaries for patients. Drug therapy for osteoporosis.
    Ann Intern Med; 2008 May; 148(9):I28. PubMed ID: 18458273
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment of osteoporosis with bisphosphonates.
    Watts NB
    Rheum Dis Clin North Am; 2001 Feb; 27(1):197-214. PubMed ID: 11285996
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacologic prevention of osteoporotic fractures.
    Zizic TM
    Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France.
    Hiligsmann M; Reginster JY
    Osteoporos Int; 2019 Mar; 30(3):649-658. PubMed ID: 30701342
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
    Netelenbos JC
    Ned Tijdschr Geneeskd; 2001 Jul; 145(28):1336-8. PubMed ID: 11484428
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
    Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
    Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Rackoff P
    Clin Interv Aging; 2009; 4():207-14. PubMed ID: 19503783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
    MMW Fortschr Med; 2007 Mar; 149(13):50. PubMed ID: 17672400
    [No Abstract]   [Full Text] [Related]  

  • 60. [Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
    Curković B
    Reumatizam; 2003; 50(2):49-50. PubMed ID: 15098377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.